Remus Pharmaceuticals Share Price

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Subsequently, Company converted in to a Public Company and changed to Remus Pharmaceuticals Limited in January 2023. Remus Pharmaceuticals Limited is a global pharmaceutical Company focused on the marketing, distribution and export of niche, specialised and complex pharmaceutical formulations. With a presence across 40+ countries, it serve diverse healthcare markets through a growing portfolio spanning multiple therapeutic areas. The Company focuses on niche, specialised and criticalcare formulations and has a strongpresence across 40+ countries in Latin America, Southeast Asia, the Middle East, CIS, Caribbean Islands, Eastern Europe and Africa.The core business of the Company into three categories, which comprise of Manufacturing, through loan licencse or on contract manufacturing bassis, of approved finished formulations and distribution of the same in various countries Trading of Active Pharmaceutical Ingredients and Technical Consultancy on preparation of reports on pharmaceutical dossiers.The product portfolio comprises of therapeutic drugs like ACE inhibitors, anaesthetic, Anti histamine, Antifungal, Antiinflammatory, Antibiotic, Antidiabetic, Antipsychotic, Antiretroviral, Chronic Obstructive Pulmonary Disease, Asthma, Carcinoid tumours, CNS stimulants, Nasal decongestants, Potassium deficiency, Probiotic, Antispasmodic, Ocularhypertension, Urology and Vitamin deficiency. The Pharma business operations are supported by various contract manufacturers having facilities which are WHO GMP Compliant. The core strength lies in getting approved formulation manufactured through contract manufacturers under loan licence and marketing of formulations through marketing network across geographies.The Company incorporated Relius Pharmaceuticals SRL as a new subsidiary Company in Bolivia, effective on October 13, 2023. The Company made an Initial Public Issue of 388000 Equity Shares of face value of Rs 10/ each by raising funds aggregating to Rs 47.68 Crore through Fresh Issue in May, 2023.The Company acquired a stake of 56.67% in Espee Global Holdings LLC, making it a subsidiary of the Company effective on January 1, 2024. The Company expanded the operational footprint to over 40 countries with Latin America in FY 2025. It strengthened presence in Bolivia by launching 10+ products via 8 pharmacy chains, 10 hospitals, and 3 subdistributors in 2025.The Company secured a direct tender covering 18 pharmaceutical products, along with Isoflurane and Sevoflurane in 2026. It expanded the urology portfolio with Mirabegron and Mirabegron + Solifenacin across select Latin American markets.